These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 16204045)

  • 1. Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor.
    Altucci L; Rossin A; Hirsch O; Nebbioso A; Vitoux D; Wilhelm E; Guidez F; De Simone M; Schiavone EM; Grimwade D; Zelent A; de Thé H; Gronemeyer H
    Cancer Res; 2005 Oct; 65(19):8754-65. PubMed ID: 16204045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autonomous rexinoid death signaling is suppressed by converging signaling pathways in immature leukemia cells.
    Benoit GR; Flexor M; Besançon F; Altucci L; Rossin A; Hillion J; Balajthy Z; Legres L; Ségal-Bendirdjian E; Gronemeyer H; Lanotte M
    Mol Endocrinol; 2001 Jul; 15(7):1154-69. PubMed ID: 11435615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.
    Riccioni R; Pasquini L; Mariani G; Saulle E; Rossini A; Diverio D; Pelosi E; Vitale A; Chierichini A; Cedrone M; Foà R; Lo Coco F; Peschle C; Testa U
    Haematologica; 2005 May; 90(5):612-24. PubMed ID: 15921376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation.
    Kamashev D; Vitoux D; De Thé H
    J Exp Med; 2004 Apr; 199(8):1163-74. PubMed ID: 15096541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential changes of retinoid-X-receptor (RXR alpha) and its RAR alpha and PML-RAR alpha partners induced by retinoic acid and cAMP distinguish maturation sensitive and resistant t(15;17) promyelocytic leukemia NB4 cells.
    Duprez E; Lillehaug JR; Gaub MP; Lanotte M
    Oncogene; 1996 Jun; 12(11):2443-50. PubMed ID: 8649786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: effects on the degradation of RARalpha and PML-RARalpha.
    Gianni' M; Kalaç Y; Ponzanelli I; Rambaldi A; Terao M; Garattini E
    Blood; 2001 May; 97(10):3234-43. PubMed ID: 11342454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAR-independent RXR signaling induces t(15;17) leukemia cell maturation.
    Benoit G; Altucci L; Flexor M; Ruchaud S; Lillehaug J; Raffelsberger W; Gronemeyer H; Lanotte M
    EMBO J; 1999 Dec; 18(24):7011-8. PubMed ID: 10601023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia.
    Kumagai T; Shih LY; Hughes SV; Desmond JC; O'Kelly J; Hewison M; Koeffler HP
    Cancer Res; 2005 Mar; 65(6):2488-97. PubMed ID: 15781666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts.
    Testa U; Grignani F; Samoggia P; Zanetti C; Riccioni R; Lo Coco F; Diverio D; Felli N; Passerini CG; Grell M; Pelicci PG; Peschle C
    J Clin Invest; 1998 May; 101(10):2278-89. PubMed ID: 9593784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel retinoic acid receptor (RAR)-selective antagonist inhibits differentiation and apoptosis of HL-60 cells: implications of RARalpha-mediated signals in myeloid leukemic cells.
    Ueno H; Kizaki M; Matsushita H; Muto A; Yamato K; Nishihara T; Hida T; Yoshimura H; Koeffler HP; Ikeda Y
    Leuk Res; 1998 Jun; 22(6):517-25. PubMed ID: 9678718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of retinoic acid receptor-alpha by granulocyte macrophage colony-stimulating factor in human myeloid leukemia cell lines.
    Shimizu T; Takeda K
    Cancer Res; 2000 Aug; 60(16):4544-9. PubMed ID: 10969805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two distinct actions of retinoid-receptor ligands.
    Chen JY; Clifford J; Zusi C; Starrett J; Tortolani D; Ostrowski J; Reczek PR; Chambon P; Gronemeyer H
    Nature; 1996 Aug; 382(6594):819-22. PubMed ID: 8752277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression.
    Xu K; Guidez F; Glasow A; Chung D; Petrie K; Stegmaier K; Wang KK; Zhang J; Jing Y; Zelent A; Waxman S
    Cancer Res; 2005 Sep; 65(17):7856-65. PubMed ID: 16140955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-resistance to retinoic acid and TRAIL by insertion mutagenesis into RAM.
    Yin W; Rossin A; Clifford JL; Gronemeyer H
    Oncogene; 2006 Jun; 25(26):3735-44. PubMed ID: 16449964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinoid-dependent growth inhibition, differentiation and apoptosis in acute promyelocytic leukemia cells. Expression and activation of caspases.
    Gianni M; Ponzanelli I; Mologni L; Reichert U; Rambaldi A; Terao M; Garattini E
    Cell Death Differ; 2000 May; 7(5):447-60. PubMed ID: 10800078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid induction of cAMP/PKA pathway during retinoic acid-induced acute promyelocytic leukemia cell differentiation.
    Zhao Q; Tao J; Zhu Q; Jia PM; Dou AX; Li X; Cheng F; Waxman S; Chen GQ; Chen SJ; Lanotte M; Chen Z; Tong JH
    Leukemia; 2004 Feb; 18(2):285-92. PubMed ID: 14628075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of CYP26A1 expression by selective RAR and RXR agonists in human NB4 promyelocytic leukemia cells.
    Idres N; Marill J; Chabot GG
    Biochem Pharmacol; 2005 Jun; 69(11):1595-601. PubMed ID: 15896339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib sensitizes human acute myeloid leukemia cells to all-trans-retinoic acid-induced differentiation by modifying the RARα/STAT1 axis.
    Ying M; Zhou X; Zhong L; Lin N; Jing H; Luo P; Yang X; Song H; Yang B; He Q
    Mol Cancer Ther; 2013 Feb; 12(2):195-206. PubMed ID: 23243061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retinoic acid receptor beta/gamma-selective prodrug (tazarotene) plus a retinoid X receptor ligand induces extracellular signal-regulated kinase activation, retinoblastoma hypophosphorylation, G0 arrest, and cell differentiation.
    Yen A; Fenning R; Chandraratna R; Walker P; Varvayanis S
    Mol Pharmacol; 2004 Dec; 66(6):1727-37. PubMed ID: 15383624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinoid receptor expression and its correlation to retinoid sensitivity in non-M3 acute myeloid leukemia blast cells.
    Lehmann S; Paul C; Törmä H
    Clin Cancer Res; 2001 Feb; 7(2):367-73. PubMed ID: 11234892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.